Excluding Abacavir in a Tivicay-based regimen is needed and I was thinking that in the future Tivicay + generic Truvada would be a good single-pill co-formulation. There are more than 20% of patients who cannot start with an NNRTI (due to primary resistance and other reasons), plus Edurant's resistance profile is even weaker than that of Sustiva, so Tivicay + Edurant would not suit also patients with high baseline viral loads. Think the dual nuke + NNRTI or PI or II will maintain the lion share of treatment.
Market Data 
Markets 
AI
